Enthusiasm, reality, and cost-effectiveness analysis.
作者信息
Brophy J M, Sleight P
出版信息
Heart. 1998 Jan;79(1):9-10. doi: 10.1136/hrt.79.1.9.
Abstract
摘要
相似文献
1
Enthusiasm, reality, and cost-effectiveness analysis.热情、现实与成本效益分析。
Heart. 1998 Jan;79(1):9-10. doi: 10.1136/hrt.79.1.9.
2
Murmurs from the heart (or why the stethoscope is not an economic tool).心脏杂音（或为何听诊器并非一种经济工具）。
Heart. 1998 Jan;79(1):10-1. doi: 10.1136/hrt.79.1.10.
3
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.评估心血管治疗价值中的经济学与成本效益。阿昔单抗的应用：比较经济数据。
Am Heart J. 1999 May;137(5):S123-5. doi: 10.1016/s0002-8703(99)70445-x.
4
The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
S Afr Med J. 1998 Feb;88(2):130-1.
5
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
Am Heart J. 1999 May;137(5):S129-32. doi: 10.1016/s0002-8703(99)70447-3.
6
Routine use of abciximab in coronary stenting?
Lancet. 1998 Jul 11;352(9122):81-2. doi: 10.1016/s0140-6736(98)85003-4.
7
8
Cost-effectiveness analysis of abciximab: a Canadian hospital perspective.
Ann Pharmacother. 1998 May;32(5):536-42. doi: 10.1345/aph.17336.
9
Cost and outcomes analysis of abciximab use in a community teaching hospital.
Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S35-7. doi: 10.1093/ajhp/55.suppl_4.S35.
10
Abciximab therapy in percutaneous intervention: economic issues in the United States.
Am Heart J. 1998 Apr;135(4):S90-7. doi: 10.1016/s0002-8703(98)70301-1.
引用本文的文献
1
Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.阿昔单抗。其在经皮冠状动脉血运重建中应用的药物经济学综述。
Pharmacoeconomics. 1999 Dec;16(6):711-41. doi: 10.2165/00019053-199916060-00009.
2
Abciximab. An updated review of its use in ischaemic heart disease.阿昔单抗。关于其在缺血性心脏病中应用的最新综述。
Drugs. 1998 Oct;56(4):629-65. doi: 10.2165/00003495-199856040-00014.
Zotero 插件